Last updated on November 2017

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris

Brief description of study

Clinical research study for the treatment of moderate to severe acne vulgaris.

Detailed Study Description

The main purpose of this study is to compare the safety, efficacy, and tolerability of a once-daily topical application of IDP-123 Lotion compared to the IDP-123 Vehicle Lotion in subjects with moderate to severe acne. Subjects must be at least 9 years of age or older and generally healthy. IDP-123 is a lotion containing 0.045% tazarotene for the topical treatment of acne. “Vehicle” is a term to describe a lotion that does not contain any active drug (similar to a placebo). If you decide to be in this research study, you may receive either the IDP-123 Lotion or the IDP-123 Vehicle Lotion. IDP-123 Lotion is called an investigational drug because it has not been approved for sale by the United States Food and Drug Administration (FDA). Because this is a research study, the topical study drug, IDP-123 Lotion, will be given to you only during this study and not after the study is over. 

Participation will be approximately 12 weeks (3 months), including 6 in office visits:

You may receive up to $400.00 if you complete the whole study, as a compensation for your time and travel.

Clinical Study Identifier: TX154540

Contact Investigators or Research Sites near you

Start Over

Valerija Misev

Juva Skin and Laser Center
New York, NY USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.